Will DOW disclose a Sadara JV impairment charge before December 31, 2026?
Current Prediction
Prediction History
Cumulative Sadara equity losses reached $1.4B commitment cap; equity loss recognition suspended under US GAAP. Restructuring with Aramco active with midyear 2026 update committed by Fitterling. Suspension is not impairment but commitment ceiling + restructuring timeline increase probability of formal impairment recognition by year-end.
Why This Question Matters
Sadara is the single largest unquantified contingent exposure in the dossier. Equity-method losses jumped 40x to $(240)M in FY25. DOW announced a strategic review for 2026. A disclosed impairment would crystallize an exposure that all seven lenses treated as latent, materially impacting GAAP results and potentially triggering debt-guarantee scrutiny. Black Swan Beacon assigns 15-25% probability to an impairment event. Resolution would either confirm the tail or validate the committee's latent-exposure assumption.
Prediction Distribution
Individual Predictions(9 runs)
Critical distinction: equity loss suspension under ASC 323 is NOT a formal impairment charge. A Sadara impairment would be a separate ASC 810/323 event where DOW writes down the equity investment below its remaining commitment balance. With the equity suspension now activated AND restructuring negotiations ongoing, the probability of a formal impairment charge during the Aramco restructuring is moderate. Restructuring outcomes that trigger impairment: (a) commitment increase followed by write-down, (b) equity dilution/restructure, (c) formal JV termination. Probability 0.30 given restructuring must conclude by year-end per Fitterling commitment.
Equity loss suspension reached $1.4B commitment ceiling. Any further funding commitment DOW makes to Sadara under restructuring would require fresh impairment test. If Aramco takes majority or DOW exits at a loss, a formal impairment is likely. Probability ~28%.
Baseline probability was 0.25 without the Q1 disclosure. The disclosure of $1.4B commitment + suspension + active restructuring pushes probability higher because: (a) the restructuring timeline is now compressed (Fitterling tied to his own transition), (b) any restructuring outcome short of status quo triggers impairment test, (c) damage from conflict (even if minor) requires assessment. Probability 0.34.
Equity loss suspension is not impairment but signals the account is at breaking point. Restructuring outcomes by year-end 2026 likely force impairment test. 30-35% probability.
Middle East supply shock ironically strengthens Sadara economically (higher petchem prices) but the geopolitical risk also raises probability of structural change in JV. Plus Fitterling's explicit midyear update schedule likely formalizes impairment decision. 0.30.
The restructuring negotiation is most likely to either terminate as status quo (very unlikely given 40x loss growth in FY25) or restructure in a way that requires formal impairment recognition. Probability leans higher — 35%.
Equity suspension + active restructuring + year-end deadline = higher impairment probability than baseline. 32%.
Probability elevated vs baseline on restructuring progression. 30%.
Base case around 30% given restructuring trajectory and commitment ceiling.
Resolution Criteria
Resolves YES if DOW discloses a goodwill, asset, or equity-method impairment charge specifically related to the Sadara JV in any quarterly earnings release, 10-Q, 10-K, or 8-K before 2026-12-31. Also resolves YES if DOW announces a Sadara equity injection, debt guarantee crystallization, or ownership restructuring that triggers an accounting impairment. Resolves NO if no such disclosure occurs by 2026-12-31.
Resolution Source
DOW 10-Q, 10-K, 8-K filings, earnings releases, and strategic review announcements
Source Trigger
Sadara JV impairment disclosed before 2026-12-31
Full multi-lens equity analysis